» Articles » PMID: 37631915

Exigency of Plant-Based Vaccine Against COVID-19 Emergence As Pandemic Preparedness

Overview
Date 2023 Aug 26
PMID 37631915
Authors
Affiliations
Soon will be listed here.
Abstract

After two years since the declaration of COVID-19 as a pandemic by the World Health Organization (WHO), more than six million deaths have occurred due to SARS-CoV-2, leading to an unprecedented disruption of the global economy. Fortunately, within a year, a wide range of vaccines, including pathogen-based inactivated and live-attenuated vaccines, replicating and non-replicating vector-based vaccines, nucleic acid (DNA and mRNA)-based vaccines, and protein-based subunit and virus-like particle (VLP)-based vaccines, have been developed to mitigate the severe impacts of the COVID-19 pandemic. These vaccines have proven highly effective in reducing the severity of illness and preventing deaths. However, the availability and supply of COVID-19 vaccines have become an issue due to the prioritization of vaccine distribution in most countries. Additionally, as the virus continues to mutate and spread, questions have arisen regarding the effectiveness of vaccines against new strains of SARS-CoV-2 that can evade host immunity. The urgent need for booster doses to enhance immunity has been recognized. The scarcity of "safe and effective" vaccines has exacerbated global inequalities in terms of vaccine coverage. The development of COVID-19 vaccines has fallen short of the expectations set forth in 2020 and 2021. Furthermore, the equitable distribution of vaccines at the global and national levels remains a challenge, particularly in developing countries. In such circumstances, the exigency of plant virus-based vaccines has become apparent as a means to overcome supply shortages through fast manufacturing processes and to enable quick and convenient distribution to millions of people without the reliance on a cold chain system. Moreover, plant virus-based vaccines have demonstrated both safety and efficacy in eliciting robust cellular immunogenicity against COVID-19 pathogens. This review aims to shed light on the advantages and disadvantages of different types of vaccines developed against SARS-CoV-2 and provide an update on the current status of plant-based vaccines in the fight against the COVID-19 pandemic.

Citing Articles

Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines.

Vo D, Trinh K Vaccines (Basel). 2025; 13(2).

PMID: 40006737 PMC: 11860421. DOI: 10.3390/vaccines13020191.


Absence of platelet overactivation and thrombosis formation among patients with coronary atherosclerosis disease after vaccination against SARS-CoV-2.

Xu H, Zhao X, Zhang P, Zhang Y, Zhou Q, Wu H Heliyon. 2024; 10(20):e38336.

PMID: 39640769 PMC: 11619953. DOI: 10.1016/j.heliyon.2024.e38336.


Exploring recent progress of molecular farming for therapeutic and recombinant molecules in plant systems.

Bharathi J, Suresh P, Prakash M, Muneer S Heliyon. 2024; 10(18):e37634.

PMID: 39309966 PMC: 11416299. DOI: 10.1016/j.heliyon.2024.e37634.


Identification of South African Plant-Based Bioactive Compounds as Potential Inhibitors against the SARS-CoV-2 Receptor.

Mkolo N, Naidoo C, Kadye R, Obi C, Iweriebor B, Olaokun O Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065672 PMC: 11279959. DOI: 10.3390/ph17070821.


Intranasal Immunization for Zika in a Pre-Clinical Model.

Shah S, Patel P, Bagwe P, Kale A, Ferguson A, Adediran E Viruses. 2024; 16(6).

PMID: 38932158 PMC: 11209107. DOI: 10.3390/v16060865.


References
1.
Xue J, Lai D, Jiang H, Qi H, Guo S, Zhu Y . Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated virus vaccine against the Omicron variant. Cell Discov. 2022; 8(1):15. PMC: 8847627. DOI: 10.1038/s41421-022-00380-8. View

2.
Yao H, Lu X, Chen Q, Xu K, Chen Y, Cheng M . Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo. Cell Discov. 2020; 6(1):76. PMC: 7595057. DOI: 10.1038/s41421-020-00226-1. View

3.
Balke I, Zeltins A . Use of plant viruses and virus-like particles for the creation of novel vaccines. Adv Drug Deliv Rev. 2018; 145:119-129. DOI: 10.1016/j.addr.2018.08.007. View

4.
Shanmugaraj B, Bulaon C, Phoolcharoen W . Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants (Basel). 2020; 9(7). PMC: 7411908. DOI: 10.3390/plants9070842. View

5.
Dhama K, Patel S, Sharun K, Pathak M, Tiwari R, Yatoo M . SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Travel Med Infect Dis. 2020; 37:101830. PMC: 7396141. DOI: 10.1016/j.tmaid.2020.101830. View